Compare Amer Sports Inc (AS) vs Summit Therapeutics Inc (SMMT) Price & Performance

Amer Sports (AS) trades at $33.67, down 6.91% over 24 hours, with a bearish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $0.38 and revenue growth of 32% year-over-year, and raised full-year guidance. Key financials show a net income margin of 6.5% and positive cash flow from operations of $729.8 million in 2025.

The outlook is supported by analyst consensus with 12 buy ratings and a $58.67 price target, but risks include high valuation multiples like a P/E of 42.3 and competitive pressures in the sports apparel sector. Near-term focus is on Q2 2026 earnings due August 18, 2026, which could drive volatility.

Summit Therapeutics (SMMT) trades at $15.42, up 3.7% with a bullish technical signal. The company shows negative profitability with ROE at -192.5% and net loss of $1.08B for 2025, but maintains positive analyst sentiment with 14 buy ratings and a $27.90 consensus price target. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials.

The investment case hinges on ivonescimab's regulatory approval potential, offering significant upside if successful. However, substantial risks include ongoing losses, cash burn requiring financing, and regulatory uncertainty. Current technical strength suggests momentum, but fundamental challenges require careful risk assessment for speculative biotech investors.